Period:
Draw Mode:
| Volume | 261,084 |
|
|||||
| News | - | ||||||
| Day High | 4.41 | Low High |
|||||
| Day Low | 4.23 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vanda Pharmaceuticals Inc | VNDA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.105 | -2.41% | 4.255 | 12:24:33 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.35 | 4.23 | 4.41 | 4.36 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,105 | 261,084 | $ 4.30 | $ 1,123,817 | - | 4.15 - 11.0425 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:27:34 | 10 | $ 4.255 | USD |
Vanda Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 244.7M | 57.51M | - | 254.38M | 6.28M | 0.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vanda Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VNDA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.46 | 4.69 | 4.23 | 4.52 | 1,030,773 | -0.205 | -4.6% |
| 1 Month | 5.21 | 5.355 | 4.15 | 4.60 | 2,455,003 | -0.955 | -18.33% |
| 3 Months | 6.56 | 6.71 | 4.15 | 5.05 | 1,179,565 | -2.31 | -35.14% |
| 6 Months | 6.81 | 7.00 | 4.15 | 5.54 | 850,769 | -2.56 | -37.52% |
| 1 Year | 9.79 | 11.0425 | 4.15 | 6.49 | 717,253 | -5.54 | -56.54% |
| 3 Years | 9.34 | 21.8627 | 4.15 | 11.03 | 561,335 | -5.09 | -54.44% |
| 5 Years | 22.96 | 33.44 | 4.15 | 13.18 | 606,302 | -18.71 | -81.47% |
Vanda Pharmaceuticals Description
| Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. |